Post renal transplantation <scp>K</scp>aposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy

Hosseini-Moghaddam, Seyed M; Soleimanirahbar, Ata; Mazzulli, Tony; Rotstein, Coleman; Husain, Shahid

doi:10.1111/j.1399-3062.2011.00714.x

Cited by 58 publications

(58 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, previous reports showed that transplant recipients were much more susceptible to post‐transplantation cancers, including KS, than the general population . In the present study, a significantly elevated incidence of KS among transplant recipients (68.59 per 100 000 person‐years) was observed compared with the general population.…”

Section: Discussionsupporting

confidence: 57%

The world‐wide incidence of Kaposi's sarcoma in the HIV/AIDS era

et al. 2018

View full text Add to dashboard Cite

Globally, a relatively high incidence of KS was found among HIV-seropositive people and, in particular, in HIV-infected MSM. The introduction of HAART has largely prevented the development of KS, but it has not entirely removed the challenge of KS. In Africa, in particular, KS imposes a very heavy disease burden, which can mainly be attributed to the high prevalence of KS-associated herpesvirus and poor access to HAART.

show abstract

Section: Discussionsupporting

confidence: 57%

The world‐wide incidence of Kaposi's sarcoma in the HIV/AIDS era

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In fact, the incidence of KS is 400–500 times higher among such patients than the general population [17]. This may be due to reactivation of latent HHV-8 virus or perhaps through acquisition of the virus from the donor organ [18]. However, certain immunosuppressants may be less likely to put patients at risk for iatrogenic KS.…”

Section: The Four Epidemiological Forms Of Kaposi’s Sarcomamentioning

confidence: 99%

An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment

Curtiss

Strazzulla

Friedman‐Kien

2016

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Kaposi’s sarcoma is an angioproliferative neoplasm which has undergone considerable epidemiologic change since the original description by Moritz Kaposi in the late 1800s. This opportunistic neoplasm gained widespread notoriety within the US during the height of the AIDS epidemic, where it was frequently found co-occurring with opportunistic infections. With the advent of modern antiretroviral therapies, as well as an increasing number of individuals on immunosuppression for autoimmune disease or organ transplantation, the landscape of the immunocompromised individual has changed. It is now important for clinicians to be mindful of Kaposi’s sarcoma manifesting in a growing variety of clinical contexts.

show abstract

“…Kaposi's sarcoma (KS) is a low-grade mesenchymal angioproliferative disorder occurring most commonly in immunocompromised individuals, such as human immunodeficiency virus (HIV)-infected patients or organ transplant recipients (1). KS is caused by the lytic replication of human herpesvirus type 8 (HHV-8/Kaposi's sarcoma-associated herpesvirus).…”

Section: Introductionmentioning

confidence: 99%

Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma

et al. 2015

View full text Add to dashboard Cite

Rituximab treatment may cause or exacerbate Kaposi's sarcoma (KS) in patients with human immunodeficiency virus (HIV)-associated multicentric Castleman's disease. Despite the widespread use of rituximab, rituximab-induced KS has not yet been reported in HIV-negative patients with diffuse large B cell lymphoma (DLBCL). We herein report a case of KS that developed after undergoing rituximab-containing chemotherapy in an HIV-negative patient with DLBCL. An 84-year-old man who received rituximab-containing chemotherapy for the treatment of DLBCL developed severe infection, and subsequently KS. Our observations indicate that serious infections under rituximab treatment may trigger KS. KS should therefore be considered when skin tumors appear in lymphoma patients receiving rituximab-containing chemotherapy.

show abstract

Post renal transplantation Kaposi's sarcoma: a review of its epidemiology, pathogenesis, diagnosis, clinical aspects, and therapy

Cited by 58 publications

References 38 publications

The world‐wide incidence of Kaposi's sarcoma in the HIV/AIDS era

The world‐wide incidence of Kaposi's sarcoma in the HIV/AIDS era

An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment

Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma

Contact Info

Product

Resources

About